History of the patients
Case | Sex/age | Site and recurrences | Treatment | Survival since | Diagnosis | Pathology | Complications - evolution | ||||||||
1st sign | 1st ocular | ||||||||||||||
1 | F/60 | O, IU, CH | Cort, top, SC | 6 m | 6 m† | Uveitis since 4 months | |||||||||
C, 4 m | Surgery | APC | OML | First treated as tuberculous meningitis | |||||||||||
Coma after craniotomy | |||||||||||||||
Pontocerebellar tumour | |||||||||||||||
O, 2nd eye 5 m, IU, CH | Cort, top | AP eye post† | OML | † | |||||||||||
2 | M/59 | C, putamen | Surgery | 6 y | 5 y† | APC | OML | ||||||||
Rx 48 Gy O + C | |||||||||||||||
O, 1 y, IU, CH | Vitr | Vitr | OML | Corneal ulcer after Rx | |||||||||||
Rx 35 Gy O | |||||||||||||||
O, 3 y, IU, CH | Vitr | Vitr | — | Cataract → ECCE + IOL | |||||||||||
Cort, top | |||||||||||||||
3 | F/75 | O + C, IU, CH, occipit, tumour | Rx 45 Gy O + C | 3 y | 3 y† | ACT | OML | Uveitis since 1 year | |||||||
Cort, SC + sys | |||||||||||||||
C, 3 y | Vertigo, gen condition↓ | ||||||||||||||
Paresis lower limb† | |||||||||||||||
4 | M/75 | O, IU, CH | Vitr | 14 m | 14 m† | Vitr | OML | Uveitis both eyes since 6 months | |||||||
Rx 50 Gy O | |||||||||||||||
C, 9 m | Subcoma cerebral extension tumour† | ||||||||||||||
5 | F/35 | O, CH, IU | Cort, top, SC, sys | 5 y | 5 y† | Vitr | — | Uveitis since 15 months both eyes | |||||||
O + M, 2nd eye IU, CH, 10 m | Vitr | Vitr | OML | ||||||||||||
Rx 45 Gy O both eyes | |||||||||||||||
Chemo (1) + (4) | |||||||||||||||
O, CH, IU 2 y | Vitr + lensect | Cataract both eyes > vision 20/20 | |||||||||||||
Cort, top | |||||||||||||||
C, cerebellum basal ganglia, 3 y | Rx 44 Gy O + C | ||||||||||||||
Chemo (1) + (4) | |||||||||||||||
O, CH, IU 4 y | Cort, top | ||||||||||||||
Vitr + lensect | |||||||||||||||
C, 5 y | Cort, sys | No more reaction† | |||||||||||||
6 | M/62 | O, IU + ret det | Vitr | 2 y | 2 y† | Vitr | OML | Uveitis since 7 months | |||||||
Cort, top, sys | Corneal ulcer | ||||||||||||||
Rx 55 Gy O | |||||||||||||||
O, 2nd eye 6 m, IU | Chemo (2) | Vitr | OML | ||||||||||||
Cort, top, sys | |||||||||||||||
C, 1 y | Rx 45 Gy O + C | Cerebral extension† | |||||||||||||
7 | M/54 | C + P, pons cerebellum | Rx45 Gy O + C | 6 m | 2 m† | Vertigo since 4 months | |||||||||
Cort, gen | CT scan tumoral masses in pons, cerebellum, lungs, corneal ulcer | ||||||||||||||
V, lungs | |||||||||||||||
O, IU + RD 4 m | Vitr + ret | Vitr | — | VA 1/20† | |||||||||||
AP eye post† | OML | ||||||||||||||
8 | M/53 | C, frontal lobe | Surgery | 6 y | 5 y | APC | — | CT scan several suggestive masses | |||||||
O, 9 m, IU | Cort, top, SC | Treated as uveitis | |||||||||||||
O, 20 m | Cort, top, SC, sys | Both eyes, glaucoma | |||||||||||||
C, 4 y, temporal lobe | Surgery | APC | OML | Cataract both eyes | |||||||||||
Rx 45 Gy + 10 Gy skull base O + C | |||||||||||||||
O, 5 y, IU + CH | Vitr, Rx 45 Gy O both eyes | Vitr | OML | Vitr + ECCE + IOL | |||||||||||
Other eye IU + cataract | |||||||||||||||
Poor general health | |||||||||||||||
9 | M/60 | V, spleen lymphadenopathy | 1 y | 1 y | Serum blood | SCL | |||||||||
O + C, 1 y, choroidal meningeal | Chemo (3) + (4) | Chorioret | SCL | ||||||||||||
Rx 30 Gy O + C | |||||||||||||||
Cort, sys |
O = ocular; C = cerebral; M = mediastinum; V = visceral; IU = intermediate uveitis; CH = chorioretinitis; RD = retinal detachment; Chor = choroidal; Age = at time of diagnosis; Chorioret = chorioretinal biopsy; Site = initital localisation and recurrences with time lapse from diagnosis; y = year(s); m = month(s); AP = anatomopathology; APC = pathology cerebral biopsy; ACT = anterior chamber tap; Vitr = vitrectomy; † = deceased; Cort = cortisone; top = topical; SC = subconjunctival; sys = systemic; Rx = radiotherapy; chemo = chemotherapy; ECCE = extracapsular cataract extraction; IOL = intraocular lens implant; OML = ocular malignant non-Hodgkin’s lymphoma; SCL = small cell non-Hodgkin’s lymphoma.
Chemotherapy: systemic: (1) Vepesid, cyclophosphamide, Adriamycin; (2) Adriablastine, cyclophosphamide, Vepesid, Oncovin, Cytosar; (3) Leukeran: intrathecal: (4) Methotrexate.